Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

BACKGROUND: Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an inadequate response to standard treatment. OBJECTIVE: To determine the clinical effectiveness, safety and cost-effectiveness of these b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health Technol Assess
Hauptverfasser: Rodgers, M, Epstein, D, Bojke, L, Yang, H, Craig, D, Fonseca, T, Myers, L, Bruce, I, Chalmers, R, Bujkiewicz, S, Lai, M, Cooper, N, Abrams, K, Spiegelhalter, D, Sutton, A, Sculpher, M, Woolacott, N
Format: Artigo
Sprache:Inglês
Veröffentlicht: NIHR Journals Library 2011
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4781419/
https://ncbi.nlm.nih.gov/pubmed/21333232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta15100
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge